目的:本研究的目的是探讨番茄红素治疗口腔潜在恶性疾病(OPMDs)的有效性的现有证据。
方法:PubMed,Scopus,WebofScience,谷歌学者,中国国家知识基础设施,和ProQuest数据库搜索到2022年4月20日。包括与活性对照或安慰剂(C)相比,评估番茄红素(I)对OPMD(P)患者的体征/症状(O)的功效的所有临床试验。使用RevMan软件(CochraneCollaboration,伦敦,英国)。
结果:共有27项临床试验(20项关于口腔粘膜下层纤维化[OSF],5口腔扁平苔藓[OLP],包括白斑2个)。总的来说,番茄红素可有效减少OSF的体征和症状,OLP,和白斑.汇总数据显示,番茄红素和泼尼松龙在减轻疼痛和促进OLP临床缓解方面的功效相当。此外,汇总数据报道了番茄红素和常规对照在改善OSF患者张口和舌突方面的疗效相当.
结论:结果显示番茄红素在减轻OSF的体征和症状方面具有良好的效果,OLP,和白斑.然而,由于观察到的异质性和较短的随访期,我们强烈建议进一步进行精心设计的研究,包括长期治疗和随访.
The aim of this study was to investigate the available evidence on the efficacy of lycopene in the management of oral potentially malignant disorders (OPMDs).
PubMed, Scopus, Web of Science, Google Scholar, China National Knowledge Infrastructure, and ProQuest databases were searched up to April 20, 2022. All clinical trials that assessed the efficacy of lycopene (I) on the signs/symptoms (O) of patients with OPMDs (P) in comparison to either active control or placebo (C) were included. Meta-analysis was conducted using the RevMan software (Cochrane Collaboration, London, UK).
A total of 27 clinical trials (20 on oral submucosa fibrosis [OSF], 5 on oral lichen planus [OLP], and 2 on
leukoplakia) were included. Overall, lycopene was efficacious in reducing signs and symptoms of OSF, OLP, and
leukoplakia. The pooled data revealed comparable efficacy of lycopene and prednisolone in reducing pain and promoting clinical resolution of OLP. Additionally, the pooled data reported comparable efficacy of lycopene and conventional controls in improving the mouth opening and tongue protrusion in patients with OSF.
The results reveal promising effects of lycopene in alleviating signs and symptoms of OSF, OLP, and
leukoplakia. However, owing to the observed heterogeneity and short follow-up periods, further well-designed studies with long-term therapy and follow-up are highly recommended.